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The purpose of this study was to quantify the effect of the fatty acid alkyl-chain length of a
polyethylene glycol (PEG) glyceryl ester, which was used as a microemulsion oil compo-
nent, on the partitioning of highly lipophilic compounds to the mesenteric lymph after oral
administration. Oil blue N, a highly lipophilic anthraquinone derivative, was orally
administered to lymph duct-cannulated and untreated rats in two kinds of different
microemulsions. Gelucire® 50/13 and Gelucire® 44/14 were used as the oil component with
long chain and medium chain fatty acid portions, respectively, of PEG glyceryl esters in
microemulsions. The cumulative amount of oil blue N in lymph fluid was almost the same
between the two microemulsions, although the transferred amount of oil component
(triglyceride) in the lymph after administration of the Gelucire® 50/13 microemulsion was
significantly higher than that of the Gelucire® 44/14 microemulsion. On the other hand, the
solubility of oil blue N in Gelucire® 44/14 was much higher than that in Gelucire® 50/13. No
significant differences were observed between microemulsions in the bioavailability of oil
blue N. From these data, the partitioning of oil blue N to the lymph was calculated using a
mathematical model, showing that the partitioning ratios of oil blue N to the lymph fluid
were almost the same for both microemulsions. The solubility of oil blue N to the oil
component of the microemulsions and the transfer of triglycerides to the lymph after
administration of the microemulsions counteract each other, leading to similar parti-
tioning ratios of oil blue N to the lymph.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).eutics, Osaka University
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Fig. 1 e Chemical structure of oil blue N.
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Recently, changes in the strategies for new drug development
have led to advances and a higher number of lipophilic, or
poorly water-soluble, compounds being tested as drug can-
didates [1]. In the case of extremely poorly water-soluble
compound which cannot be expected to show enough
bioavailability, it has to be developed as parenteral formula-
tions such as an injection, or the definition of maximum
tolerated dose and toxicity testing are also impracticable due
to low solubility because higher dose is needed for these
study; therefore, strategies for developing new oral dosage
forms are necessary to increase the intestinal absorption. One
of the ways to resolve this issue, the utilization of lipid
dispersion systems, is promising because of their potential to
dissolve highly lipophilic drugs [2e4].
Triglycerides can be absorbed as a component of a
formulation that permeates the intestinal epithelial cell
membrane after hydrolysis to free fatty acids and mono-
glycerides by pancreatic lipase in the intestinal tract, as well
as following ingestion as dietary lipids. Subsequently, tri-
glycerides are reconstructed in the endoplasmic reticulum of
the intestinal epithelium and released into the mesenteric
lymph duct as chylomicrons, comprising apolipoprotein and
cholesterol in the Golgi apparatus. Triglycerides transferred to
the mesenteric lymph finally reach the systemic circulation
via the thoracic lymph; therefore, the intestinal absorption of
the lipophilic drugs administered in lipid dispersion systems,
such as emulsions, can be affected by the absorption of tri-
glycerides concomitantly administered as a component of
formulations [5,6]. By means of a model-based quantitative
analysis, we previously clarified that the amount of a com-
pound absorbed via the lymph ducts is related to both the
partitioning of the compound loaded in the emulsion to the
lymph route after oral administration, which is determined by
the solubility of the compound in the triglyceride in the
emulsion, and the amount of triglyceride transferred into the
lymph duct [7]. We also showed that the longer the fatty acid
alkyl-chain length of the triglyceridemaking up the emulsion,
the more triglyceride transferred to the lymph fluid [7].
In recent years, microemulsions have been much antici-
pated as a novel dosage formulation for highly lipophilic drugs
[8,9]. A microemulsion is defined as a dispersion system
composed of oil/surfactant/co-surfactant/water, which is
transparent and thermodynamically stable [10]; therefore, it
can dissolve highly lipophilic drugs in its core oil phase. For
example, Neoral®, a self-microemulsifying drug delivery sys-
tem (SMEDDS) including cyclosporin A, and has been used
clinically [11]. It has been reported that orally administered
Neoral® forms a microemulsion by contacting and mixing
with the intestinal fluid, thereby improving the intestinal ab-
sorption of cyclosporin A and decreasing the variation in the
amount of intestinally absorbed drug [12].
Gelucire®s are the most frequently used excipients as they
are powerful solubilizing agents and bioavailability enhancers
by oral and topical routes. Both Gelucire® 44/14 (lauroyl mac-
rogolglycerides) and Gelucire® 50/13 (stearoyl macro-
golglycerides) have unique compositions of amphiphilic lipids
produced by induction of polyethylene glycol (PEG) toglyceride groups; therefore, they are used for oral dosage
formulations of highly lipophilic drugs either by themselves or
in combination with other co-surfactants. However, the ef-
fects of the fatty acid alkyl-chain length of a PEG glyceryl ester
in amicroemulsion on the drug absorptionmechanismand/or
drug absorption enhancement mechanism are not fully un-
derstood in situationswhere amicroemulsion is administered
as a lipid-based formulation.
In this study, we preparedmicroemulsions using Gelucire®
44/14 or Gelucire® 50/13 as an oil phase, a mixture of Cremo-
phor ELR/ethanol ¼ 3/1 as a surfactant/co-surfactant, and
water, and used oil blue N as a model highly lipophilic com-
pound (Fig. 1). The effect of the fatty acid alkyl-chain length of
a PEG glyceryl ester in a microemulsion on both the parti-
tioning of highly lipophilic compounds to the mesenteric
lymph and intestinal absorption enhancement were exam-
ined in rats.2. Materials and methods
2.1. Materials
Oil blue N and Cremophor® EL were purchased from Sigma
Chemical Co., Ltd. (St. Louis, MO, USA). Gelucire® 44/14
(lauroyl macrogolglycerides) and Gelucire® 50/13 (stearoyl
macrogolglyceride) were kind gifts from Gattefosse (Genne-
villiers Cedex, France). The ethanol was from Nacalai Tesque
Co., Ltd. (Kyoto, Japan). The purity of oil blue N and ethanol
weremore than 98% and 99.5%, respectively, and that of other
chemicals including Cremophor® EL, Gelucire® 44/14, and
Gelucire® 50/13 were more than 95%.
2.2. Construction of a pseudo-ternary phase diagram of
microemulsions
The pseudo-ternary phase diagrams of oil, surfactant/co-
surfactant, and water were constructed at room temperature
using thewater titrationmethod [13,14]. Briefly,mixtureswith
various compositions of oil and surfactant/co-surfactant were
prepared at 60 C. The adequate volume of water was added
while stirring at 60 C. The mixture was sonicated at 40 W for
2 min using an Ultrasonic Disrupter UD-201 (Tomy Co., Tokyo,
Japan) and put into the well of a titration plate. The plate was
left for 24 h at room temperature. The turbidity of each sample
was determined by measuring the absorbance at 600 nm.
The samples that showed no turbidity were identified as
microemulsions.
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Oil blue N (clogP ¼ 4.73, Sci. Finder; CAS, Columbus, OH) was
used as a model poorly water-soluble compound. The chem-
ical structure of oil blue N is shown in Fig. 1. The weight ratio
of each composition of microemulsion used in this study was
fixed to oil/(surfactant/co-surfactant)/water ¼ 1/1/8 according
to the results of the pseudo-ternary phase diagram. Either
Gelucire® 44/14 or Gelucire® 50/13 was used as the oil and
Cremophor® EL and ethanol were used as a surfactant and co-
surfactant, respectively. The weight ratio of surfactant/co-
surfactant was fixed to 3/1 for both microemulsion formula-
tions because the highest solubility of oil blue N was observed
at this ratio (data not shown). The preparation of the micro-
emulsions was performed according to themethod of Ito et al.
[15]. Briefly, the adequate weights of oil, surfactant, and
co-surfactant were mixed at 60 C. Oil blue N was added to
the mixture and sonicated at 40 W for 2 min. Water was
then added to the mixture while stirring at 60 C. The oil blue
N concentration in each microemulsion was adjusted to
1.2 mg/ml.2.4. Measurement of the droplet size of the
microemulsions
The droplet size of themicroemulsions wasmeasured at 37 C
using the dynamic light scattering technique with a Zeta sizer
nano-S (Malvern instruments, Ltd., Worcestershire, UK).2.5. In vivo oral administration to rats with non-
cannulated lymph ducts
All animal experiments were approved by the Animal Exper-
imentation Committee of the Osaka University of Pharma-
ceutical Sciences. Male Wistar rats weighing 300e350 g were
obtained from Japan SLC, Inc. (Shizuoka, Japan). Rats were fed
and given drinking water ad libitum, and housed under a 12-h
lightedark cycle for at least 2 weeks before the experiment.
Rats were divided into two groupswith 4 rats in each group for
all the experiments. The day before the experiment, the rats
were lightly anesthetized with ether, and were implanted
surgically with a combination of phicon (Fuji Systems Ltd,
Tokyo, Japan) and PE50 (Clay Adams, Parsippany, NJ, USA) in a
catheter, which was inserted into the right jugular vein for
blood sampling. The catheter was externalized through the
back of the neck and secured. After recovery, rats were fasted
but drinking water was supplied ad libitum for 16 h before the
experiment. After a sufficient recovery period, 0.5 ml of each
microemulsion formulation was orally administered using a
stomach catheter and 400 ml of blood was periodically with-
drawn from the jugular vein at a predetermined time interval
for 8 h. Blood was centrifuged at 7400 g for 5 min to obtain a
plasma sample. Plasma samples were kept at 20 C until use
in the assay. For calculating the bioavailability, the concen-
tration of oil blue N in the plasma after intravenous injection
of 120-mg oil blue N was used as per data we previously re-
ported [7]. To keep the rats with cannulated lymph ducts
under the same conditions, the rat abdomens were incised
and sutured as a sham operation.2.6. In vivo oral administration to rats with cannulated
lymph ducts
To measure the transfer of oil blue N into the lymph fluid, the
rat abdomen was incised and a catheter (0.8 mm, Natsume
Seisakusho Co., Ltd., Tokyo, Japan) was inserted into the
thoracic lymph duct under sodium pentobarbital anesthesia
(i.p. 50 mg/kg of body weight). After the catheter was exter-
nalized, the abdominal incision was sutured. The rats were
restrained in a Ballman cage and were fasted for 16 h before
the experiment, but drinking water was supplied ad libitum.
Each microemulsion formulation (0.5 ml) was orally admin-
istered and lymphfluidwas collected into a clear glass tube for
8 h, with the glass tube exchanged for a new one every hour.
The endpoint of blood and lymph fluid sampling was set at 8 h
because we found, in a preliminary experiment, that both
intestinal absorption and the lymphatic transfer of oil blue N
ended within 8 h of oral administration. Lymph fluid and
plasma samples were kept at 20 C until use in the assay.
2.7. Determination of oil blue N concentration in the
plasma
An 800-ml aliquot of phosphate-buffered saline (pH 7.4) and
10 ml of internal standard solution (Solvent blue 59 dissolved in
dimethyl sulfoxide [20 mg/ml]) were added to the plasma
sample (200 ml). Subsequently, 2 ml of chloroform was added,
and the mixture was vigorously shaken for 10 min. After
centrifugation at 1200 g for 10 min, the organic phase was
transferred into another tube and evaporated in vacuo. Meth-
anol (150 ml) was added for reconstitution and a 50- ml sample
was injected into a high-performance liquid chromatography
(HPLC) system (JASCO Co., Tokyo, Japan). The area under the
compound concentrationetime curve (AUC) was calculated
using the linear trapezoidal method, and the AUC extending
beyond the last data sampling pointwas estimated by dividing
the concentration in the plasma at 8 h after administration by
the terminal slope.
2.8. Determination of oil blue N and triglyceride
concentration in the lymph fluid
Methanol (500 ml) was added to 20 ml of the lymph fluid sample,
and themixturewas vigorously shaken for 1min. Themixture
was centrifuged at 5300 g for 4 min, and 50 ml of the super-
natant was injected into the HPLC system.
The amount of triglyceride transferred to the mesenteric
lymph after oral administration of eachmicroemulsion to rats
wasdeterminedbymeasuring the triglyceride concentration in
the lymph fluid using a commercial kit (Triglyceride E Test
WAKO, Wako Pure Chemicals Co., Ltd., Osaka, Japan). As a
controlexperiment, the triglycerideconcentration inthe lymph
fluid after oral administration of 0.5 ml of water was deter-
mined ina similarmanner to thatused for themicroemulsions.
2.9. Solubility of oil blue N in the Gelucire®s
The solubility of oil blue N in Gelucire® 44/14 and Gelucire® 50/
13 was measured using the conventional flask-shaking
method. Gelucire® 44/14 and Gelucire® 50/13 are considered
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tion in the intestinal epithelium. To determine the solubility,
10% Gelucire®s in water was used because they are semi-solid
at 37 C. An excess amount of oil blue N was added to 3 ml of
each solution and stirred for 12 h at 37 C. The samples were
centrifuged at 7400 g for 5 min. The supernatant was filtered
and diluted with acetonitrile and the oil blue N concentration
was measured using a spectrophotometric method. The
absorbance of oil blue N in acetonitrile was measured at
spectrum of 644 nm.
2.10. Evaluation of the effects of the microemulsions on
the intracellular disposition of oil blue N
An orally administered highly lipophilic drug is taken up by
epithelial cells; thereafter, a fraction of the drug enters the
chylomicron and is released into the mesenteric lymph duct.
Consequently, drugs absorbed via the lymphatic route avoid
the hepatic first-pass effect. We previously reported that
quantitative analysis of the partitioning of highly lipophilic
compounds to the mesenteric lymph in intestinal cells
possible using the following equations [7]. The total absorbed
amount of a highly lipophilic drug after oral administration
can be quantitatively described by the sum of the drug
amount absorbed via the portal route and that absorbed by the
lymphatic route (Fig. 2); therefore, the following equation
(eq. (1)) is obtained:
Dpo  F ¼

Dpo  Fa  Fg  fportal  Fh

þ

Dpo  Fa  Fg  flymph

(1)
where, Fa is the fraction of the dose taken up by the intestinal
cells, and Fg and Fh are the fractions of the dose that are notFig. 2 e Pathway of highly lipophilic compounds to the systemic
Fa, fraction of dose taken up by intestinal cells; Fg, fraction of do
metabolized in the liver; flymph, ratio of the amount transferredmetabolized in the intestine and liver, respectively. fportal and
flymph are the ratio of the amount transferred to the portal vein
and mesenteric lymph duct, respectively, to the amount that
is not metabolized in the intestinal epithelial cells. The rela-
tionship between fportal and flymph can be expressed as follows:
fportal þ flymph ¼ 1 (2)
In the experiment in which rats with cannulated lymph
ducts were used, the total amount of drug absorbed via the
lymphatic route (Alymph) can be obtained. The ratio of the
amount absorbed via the lymphatic route to the total amount
absorbed after oral administration (ROL) can be described
using eqs. (1) and (2) as follows:
ROL ¼ Dpo  Fa  Fg  flymph
Dpo  Fa  Fg  fportal  Fh

þ

Dpo  Fa  Fg  flymph

¼ flymph
1 flymph

 Fh þ flymph
¼ Alymph
Dpo  F (3)
A value of 0.824 ± 0.021 is used as the Fh from our previous
report [7]. By substituting Alymph and F obtained from the ex-
periments in eq. (3), the flymph was calculated to consider the
effect of each microemulsion on the intracellular disposition
of oil blue N.2.11. HPLC conditions
The concentrations of oil blue N in the samples were deter-
mined by reversed-phase HPLC on a Mightysil RP-18 GP col-
umn (250  4.0 mm, 5 mm). The HPLC system consisted of a
PU-980 pump, UV-970 UV-VIS spectrophotometric detector
(JASCO Co., Tokyo, Japan), and C-R6A integrator (Shimadzucirculation. Dpo, amount absorbed after oral administration;
se not metabolized in the intestine; Fh, fraction of dose not
to the mesenteric lymph duct.
Fig. 3 e Pseudo-ternary phase diagram of microemulsions.
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and was run at a flow rate of 1.5 ml/min. The UV-VIS detector
was set at 644 nm. The method exhibited a linear range of
10e1000 ng/ml in blank rat plasma and lymph fluidwith lower
detection limit of 5 ng/ml. The intra- and inter-assay co-
efficients of variation did not exceed ±12% from the nominal
concentration. The accuracy of oil blue N was within ±9% of
the theoretical value.
2.12. Statistical analysis
All values are expressed as the mean ± standard deviation of
the mean (SD). The statistical analyses were performed using
the ManneWhitney U test. The level of significance was set at
p < 0.05.3. Results and discussion
3.1. Characterization of Gelucire® 44/14 and Gelucire®
50/13 microemulsion
Microemulsion is the most promising formulation to enhance
theoralbioavailabilityofhighly lipophilicdrugs [16,17]because
it can dissolve these compounds in its core oil phase; however,
it is composed of oil/surfactant/co-surfactant/water and is a
more complex system than emulsion. we prepared micro-
emulsions using Gelucire® 44/14 or Gelucire® 50/13 as an oilTable 1 e Effects of fatty acid alkyl-chain length of the oil comp
the mesenteric lymph.
Parameters Gelucir
Solubility to oil component (mM)
F
Cumulative amount of oil blue N in lymph fluid (% of dose)
ROL
flymph
The solubility of oil blue N in the Gelucire®s was measured using 10% Gel
route to the total amount absorbed after oral administration; flymph, ratiophase, a mixture of Cremophor ELR/ethanol ¼ 3/1 as a
surfactant/co-surfactant, and water.
The pseudo-ternary phase diagrams of oil, surfactant/co-
surfactant, and water used for the formation of the micro-
emulsions are shown in Fig. 3. Microemulsions were formed
using both Gelucire®s as an oil composition. The region of
microemulsion formation for Gelucire® 44/14was greater than
that for Gelucire® 50/13. According to this result, the compo-
sition of the microemulsions was determined as Gelucire® 44/
14 or Gelucire® 50/13/(Cremophor EL/ethanol)/water ¼ 1/1/8
and the Cremophor® EL/ethanol ratio was fixed to 3/1 for
further experiments.
The mean volume diameter and size distribution of each
microemulsion was measured using the dynamic light scat-
tering method. The mean volume diameters of the Gelucire®
44/14 and Gelucire® 50/13microemulsionswere 12.3 ± 2.62 nm
and 10.6 ± 1.62 nm, respectively. No significant differences in
mean diameter and size distribution were observed between
microemulsions.3.2. Solubility of oil blue N to the oil component of
microemulsions
The solubility of oil blue N to 10% Gelucire®s in water is listed
in Table 1. The solubility of oil blue N to 10% Gelucire® 44/14 is
approximately 3-fold higher than that to 10% Gelucire® 50/13.
This result shows that oil blue N has a greater affinity for theonent in microemulsions on the partitioning of oil blue N to
e® 44/14 microemulsion Gelucire® 50/13 microemulsion
0.249 ± 0.004 0.083 ± 0.006
0.496 ± 0.041 0.385 ± 0.036
35.67 ± 0.66 29.19 ± 4.31
0.720 0.761
0.679 ± 0.046 0.724 ± 0.022
ucire®s in water. ROL, ratio of the amount absorbed via the lymphatic
of the amount transferred to the mesenteric lymph duct.
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acid alkyl-chain length.3.3. Effect of the alkyl-chain length of the fatty acid
portion of a PEG glyceryl ester in microemulsion on the
transfer of oil blue N to the lymph fluid
The enhanced bioavailability of lipophilic compounds in
microemulsions may also be caused by absorption via the
lymphatic route. It is very important for the development of
formulations to clarify the difference in the mechanism of
enhancing intestinal absorption for highly lipophilic drugs
between emulsion and microemulsion preparations.
The time course of the cumulative amount of oil blue N
recovered in the lymph fluid after oral administration to rats
with cannulated lymph ducts is shown in Fig. 4. When
administered in each microemulsion, oil blue N was detected
in the lymph fluid as early as 1 h after administration, and the
recovered amounts gradually increased. The cumulative
amount of oil blue N stabilized within 8 h of administration.
The total amounts of oil blue N recovered in the lymph fluid
after administration in the Gelucire® 44/14 andGelucire® 50/13
microemulsions were 35.7 ± 0.7% and 29.2 ± 4.3%, respec-
tively. No significant difference in total recovered amount was
observed between the two microemulsions. This result shows
thatmicroemulsion aswell as emulsion preparations promote
the absorption of oil blue N via the lymphatic route since no
absorption was observed after administration as a suspension
form [7]. We previously showed that the cumulative amount
of oil blue N in the lymph fluid after administration in emul-
sion was dependent on the chain length of the fatty acid
portion of a triglyceride in an emulsion, and that a long-chain
triglyceride emulsion showed a value of 23.6 ± 3.1% [7]. This
suggests that a microemulsion preparation provides an
enhancement to the transfer of oil blue N to the lymph than
does an emulsion preparation. Generally, it is considered that
the highly lipophilic compounds show the high affinity to the
oil component with a longer fatty acid alkyl-chain length. In
fact, the order of the alkyl-chain length of fatty acid portion of
oil was good agreementwith that of the cumulative amount of
oil blue N in the lymphatic fluid after administration in
emulsions [7]. On the other hand, no tendency was shown forFig. 4 e Cumulative amount of oil blue N in lymph fluid
after oral administration in microemulsions to rats.the microemulsions; therefore, the mechanism of the
lymphatic transfer of highly lipophilic compound is probably
different between emulsions and microemulsions.3.4. Comparison of the amount of triglyceride in
microemulsion transferred to the lymph fluid after oral
administration
Highly lipophilic compounds, such as oil blue N used in this
study, possibly transfer to themesenteric lymphwith the flow
of the oil component (alkyl-macrogolglycerides) of the
microemulsion. We measured the amount of triglyceride in
the lymph fluid after oral administration of the micro-
emulsions as an index of the transfer of lipid formulation to
the lymph. As shown in Fig. 5, the cumulative amount of tri-
glyceride in the lymph fluid 8 h after administration of Gelu-
cire® 44/14 and Gelucire® 50/13 microemulsions reached
42.03 ± 2.92 mg and 62.21 ± 6.48 mg, respectively. In the con-
trol group, the cumulative amount of triglyceride in the lymph
was 21.55 ± 2.39 mg. Compared to the control group, both
microemulsions significantly increased the amount of
triglyceride transferred to the lymph. The concentration of
triglyceride in the lymph fluid after administration of the
Gelucire® 50/13 microemulsion was significantly higher than
that after the Gelucire® 44/14 emulsion. This suggests that
microemulsions composed of oil with a long fatty acid alkyl-
chain provide greater enhancement of the transfer of triglyc-
eride to the lymph than those with a medium alkyl-chain
triglyceride portion. This result is in agreement with our pre-
vious reports using emulsions [7]. Khoo et al. [18] also reported
that the triglyceride amount transferred into the lymph fluid
after oral administration of a microemulsion composed of
long-alkyl chain triglycerides as an oil component to dogs was
approximately 4-fold higher than that of a microemulsion
with a medium-alkyl chain triglyceride. The drugs absorbed
via this route can avoid the hepatic first-pass effect; therefore,
not only emulsions but also microemulsions are expected toFig. 5 e Cumulative amount of oil component (PEG glyceryl
ester of fatty acid) of microemulsions in lymph fluid after
oral administration to rats.
Fig. 6 e Concentration of oil blue N in plasma after oral
administration in microemulsions to rats.
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highly lipophilic compounds.
3.5. Enhancing effect of intestinal absorption of oil blue
N by microemulsion
Differences in the amount of a drug absorbed via the lymphatic
route may alter its bioavailability after oral administration
becausedrugsabsorbedvia thisroutecanavoid thehepaticfirst-
pass effect. To confirm the effects of microemulsions on the
bioavailability of oil blue N, we measured the oil blue N con-
centration in plasma after oral administration in rats without
cannulated lymph ducts. The concentration of oil blue N in the
plasma after oral administration are shown in Fig. 6. When
administered inbothmicroemulsions,oil blueNwasdetected in
the plasma samples. The concentration of oil blue N in plasma
was ranked Gelucire® 44/14 microemulsion  Gelucire® 50/13
microemulsion for each sampling point. The calculated bio-
availabilities of oil blue N are listed in Table 1. No significant
differences in bioavailability were observed between the Gelu-
cire® 44/14 (0.496 ± 0.046) and Gelucire® 50/13 (0.385 ± 0.036)
microemulsions; however, these values were significantly
higher than that in the long-chain triglyceride emulsion that
showed the highest bioavailability (0.284± 0.028) of oil blueN in
our previous study [7].
Taken together, the affinity (i.e., solubility) of oil blue N to
Gelucire® 44/14 is higher than that to 50/13 Gelucire®. On the
other hand, the triglyceride amount transferred to the lymph
after administration of the 50/13 Gelucire® emulsion was
higher than that of the Gelucire® 44/14 emulsion, with the
result that the amount of oil blue N transferred to the lymph
fluid was comparable between both microemulsions because
of these factors counteracting.
3.6. Quantitative evaluation of the partitioning of oil
blue N to the lymphatic route after oral administration in
microemulsion
An orally administered drug is taken up by the intestinal
epithelial cells, and thereafter, partitioned into the lymph;therefore, the drug amount taken up in the epithelial cells
greatly affects the amount of drug transferred to the lymph.
We performed quantitative analysis of the drug disposition in
the intestinal cells using the results of in vivo oral adminis-
tration experiments.
By substitution of Alymph, the bioavailability and Fh values
in eq. (3), the ROL, and flymph were calculated and these are
listed in Table 1. The flymph values after administration in the
Gelucire® 44/14 and Gelucire® 50/13 microemulsions were
0.679 ± 0.046 and 0.724 ± 0.022, respectively. The ROL values
for Gelucire® 44/14 and Gelucire® 50/13 microemulsion were
0.720 and 0.761, respectively. No significant differences were
observed between microemulsions for either parameter. A
reasonable explanation for the comparable flymph values be-
tween the 50/13 and 44/14 Gelucire® microemulsions is that
the affinity of oil blue N to the oil component of the micro-
emulsions and the transfer of triglyceride to the lymph after
their administration counteract each other. To increase in-
testinal absorption via the lymph route, it is effective to use a
formulation including an oil component that increases both
drug solubility and the flow of triglyceride to the lymph.4. Conclusion
We clarified that the partitioning of highly lipophilic com-
pounds in the intestinal cells to themesenteric lymphafteroral
administration in microemulsion is independent on the chain
length of the fatty acid portion of an oil component of micro-
emulsions using the mathematical model. The enhancing
mechanism of intestinal absorption of highly lipophilic com-
pounds by micromelusions is probably different from that by
emulsions.r e f e r e n c e s
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